Related Experiment Videos
Effect of imexon treatment on Friend virus complex infection using genetically defined mice as a model for HIV-1
J D Morrey1, R P Warren, K M Okleberry
1AIDS Research Program, Utah State University, Logan 84322-5600.
Abstract:
Imexon (4-imino-1,4-diazobicyclo-3.1.0-hexan-2-one) was moderately effective in the treatment of a retroviral infection in a genetically defined murine model. The animal model consisted of a Friend virus complex (FV) infection in a hybrid mouse strain, (B10.A x A/WySn)F1, which has similarities with acquired immune deficiency syndrome (AIDS). Intraperitoneal imexon initiated 1 or 3 days after FV inoculation and continued through 13 days after inoculation significantly reduced splenomegaly, splenic cell-free virus titers and viral RNA. Viral infectious centers/10(6) splenocytes and FV titers in the plasma were reduced, though not to a statistically significant level. The effect of imexon on survival was not statistically significant which suggested that the antiviral effects were only transiently effective. Phytohemagglutinin-induced blastogenesis and percent of total T cells, T helper cells and T suppressor/cytotoxic cells in the spleens were increased, and the percentage of B cells decreased by imexon treatment of both FV-infected and uninfected mice. The splenic natural killer cell activity and interleukin-1 production were not markedly affected. Virus specific neutralizing antibody developed in both imexon- and placebo-treated FV-infected mice, although titers were lower in the imexon-treated animals.
Insights
Imexon showed moderate effectiveness in treating a retroviral infection in mice, reducing viral load and improving immune cell activity. However, its impact on survival was not significant, suggesting transient antiviral effects.
Area of Science:
- Immunology
- Virology
- Pharmacology
Background:
- Retroviral infections pose significant health challenges, with models like the Friend virus complex (FV) in mice offering insights into acquired immune deficiency syndrome (AIDS) pathogenesis.
- Understanding the immunomodulatory effects of potential therapeutic agents is crucial for developing effective antiviral strategies.
Purpose of the Study:
- To evaluate the efficacy of Imexon as a treatment for retroviral infections using a murine model.
- To assess Imexon's impact on viral load, splenomegaly, immune cell populations, and survival rates in infected mice.
Main Methods:
- A genetically defined murine model (B10.A x A/WySn)F1 infected with Friend virus complex (FV) was used.
- Imexon was administered intraperitoneally at specific time points post-infection.
- Measurements included viral titers, viral RNA, splenomegaly, splenocyte counts, T cell subsets, B cells, natural killer cell activity, and antibody production.
Main Results:
- Imexon significantly reduced splenomegaly, splenic cell-free virus titers, and viral RNA in FV-infected mice.
- While viral infectious centers and plasma FV titers decreased, these reductions were not statistically significant.
- Imexon treatment increased T cell populations and blastogenesis but decreased B cells; splenic natural killer cell activity and IL-1 production remained largely unaffected.
Conclusions:
- Imexon demonstrated moderate antiviral activity and immunomodulatory effects in a murine retroviral infection model.
- The observed antiviral effects were transient, as Imexon did not significantly improve survival rates.
- Further research may be warranted to explore Imexon's potential in combination therapies or for specific immunomodulatory purposes.